Table 2. Summary of the roles of miRNAs associated with diagnosis and prognosis, type of tissue taken, number of sample taken, and discovery platform used.
| MiRNAs | Up/down-regulated | Diagnosis/prognosis | Type of tissue | No. of samples | Discovery platform | References |
|---|---|---|---|---|---|---|
| MiR-21 | Up-regulated | Diagnosis and prognosis both | Blood/serum | 94 patients with primary EOC | Real-time RT-PCR assay | 78 |
| MiR-141, miR-200a/b/c | Up-regulated | Diagnosis | Tissue sample | 84 snap-frozen normal and malignant ovarian tissues | MiRNA microarray hybridization | 30,40 |
| MiR-199, miR-140, miR-145, miR125b | Down-regulated | Diagnosis | Tissue sample | 84 normal and malignant ovarian tissues | MiRNA microarray hybridization | 30 |
| MiR-484, miR-642, and MiR-217 | Down-regulated | Prognosis | Tumor tissue | 112 EOC samples | Quantitative RT-PCR | 79 |
| MiR-221 | Up-regulated | Diagnosis and prognosis | Serum | 96 patients with EOC | Real-time RT-PCR assay | 68 |
| MiR-31 | Down-regulated | Chemoresistance | KFr13Tx cell lines | - | Real-time PCR | 67 |
| MiRs-21, 92, 93, 126 and 29a | Up-regulated | Diagnosis and prognosis | Serum | 28 patients with EOC | TaqMan real-time PCR | 74 |
| MiRs-155, 127 and 99b | Down-regulated | Diagnosis and prognosis | Serum | TaqMan real-time PCR | 74 | |
| MiR-182 | Up-regulated | Prognosis (chemoresistance) | Tumor tissue as well as cell lines | 15 ovarian tissue samples and 2 cell lines | Real-time PCR | 80 |
| MiR-23a, miR-27a, miR-21 and miR24-2 | Up-regulated | Prognosis | Tumor tissue sample | 56 ovarian cancer samples | Microarrays. | 75 |
| MiR-21, 141, 200a, 200b, 200c, 203, 205, and 214 | Up-regulated | Diagnosis | Serum | 50 ovarian cancer patients | MiRNA-microarrays | 73 |
| MiR-30c, 30d, 30e-3p, and 370 | Up-regulated | Clinicopathologic variables | Ovarian cancer tissue block | 171 Formalin fixed paraffin embedded tissue | Taqman based RT-PCR | 72 |
| MiR-221 | Up-regulated | Prognosis | Serum | 96 EOC samples | Real-time PCR | 81 |
| Let-7i | Down-regulated | Prognosis (chemotherapy response) | Tissue sample | 72 patients and 4 ovarian cancer cell lines | MiRNA-microarrays | 34 |
| MiR-9 | Down-regulated | Diagnostic for recurrent ovarian cancer | Tissue sample | 18 fresh frozen and 22FFPE EOC samples | Real-time PCR | 82 |
| MiR-223 | Up-regulated | Diagnostic for recurrent ovarian cancer | Tissue sample | 18 fresh frozen and 22FFPE EOC samples | Real-time PCR | 82 |
EOC, epithelial ovarian cancer.